Medical/Pharmaceuticals
Peijia Medical Obtained Exclusive License for JenaValve's Trilogy TAVR System for Treating AR in the Greater China Region
SUZHOU, China, Jan. 19, 2022 /PRNewswire/ -- Peijia Medical Limited (HKEX: 9996) is pleased to announce its strategic investment and exclusive in-licensing agreement with JenaValve Technology, Inc. Under the terms of the agreement, Peijia has made a cash and equity investment in JenaValve and wil...
2022-01-19 20:00
4507
Seegene to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing
SEOUL, South Korea, Jan. 19, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, announced today the upcoming launch of the Allplex™ SARS-CoV-2 Fast PCR Assay, which can deliver PCR results in just 60 minutes. The company says that this assay is exp...
2022-01-19 20:00
2766
Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings
* Purchase of Assets and Related Global Commercialization Rights for Oral 9- cis-Retinol (Zuretinol) for Rare Forms of Childhood Blindness. * Clinical Stage Asset Has Potential for First Approved Oral Therapy for Leber's Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP) Caused by Mutati...
2022-01-19 19:49
2415
Octapharma puts a spotlight on the challenges of managing inhibitors in haemophilia A at the 15th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
LACHEN, Switzerland, Jan. 19, 2022 /PRNewswire/ -- The virtual symposium held on Wednesday, February 2, 2022, at 18:00 CET, will tell the story of the Rodriguez family and their two sons with haemophilia A as they navigate the challenges of inhibitor management. The development of inhibitors to r...
2022-01-19 19:00
2701
Accomplished Pharma R&D leader, Sauri Gudlavalleti joins Sai Life Sciences as Chief Operating Officer
HYDERABAD, India, Jan. 19, 2022 /PRNewswire/ -- Sai Life Sciences, a leading
globalContract Research, Development & Manufacturing Organization
2022-01-19 18:30
4653
Good news to patients with corneal blindness: MIOK Keratoprosthesis, the World's First Artificial Cornea of 100% Non-biological Materials has been approved for listing in China.
BEIJING, Jan. 19, 2022 /PRNewswire/ -- On December 7, 2021, MIOK Keratoprosthesis was approved for listing by NMPA, the Chinese agency for regulating drugs and medical devices. MIOK Keratoprosthesis is the world's first ever approved artificial cornea that requires no co-implantation of donor co...
2022-01-19 12:25
4256
XtalPi Partners with Excelra for GOSTAR to Enhance its Intelligent Digital Drug Discovery and Development platform
HYDERABAD, India and SHENZHEN, China, Jan. 19, 2022 /PRNewswire/ -- Excelra, a leading global Data & Analytics organization, today announced the partnership for its Global Online Structure Activity Relationship Database (GOSTAR) with XtalPi Inc., an AI-based pharmaceutical biotechnology company r...
2022-01-19 09:00
10308
ImmVira's MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data
SHENZHEN, China, Jan. 18, 2022 /PRNewswire/ -- ImmVira's breakthrough product MVR-T3011 IV, global first clinical-stage oncolytic herpes simplex virus (oHSV) via intravenous injection, has recently completed first 2 cohorts dose-escalation of U.S. Phase I clinical study, and demonstrated good saf...
2022-01-19 08:30
2120
Transplant Connect to Expand Human Biologics Management Software with Investment from InVita Healthcare Technologies
LOS ANGELES, Jan. 19, 2022 /PRNewswire/ -- Transplant Connect, the world's leading software provider for the donation and transplantation field, is pleased to announce an investment from InVita Healthcare Technologies. InVita provides leading chain of custody software for complex medical environm...
2022-01-19 08:28
2208
CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients
* Sugemalimab is the world's first PD-L1 monoclonal antibody that when administered along with chemotherapy improved overall survival of first-line metastatic squamous and non-squamous non-small cell lung cancer patients in a statistically significant and clinically meaningful manner * Surviv...
2022-01-19 08:05
4603
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Ankylosing Spondylitis
HANGZHOU, China, Jan. 19, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced today that the first patient has been dosed with LNK01001 in its Phase II clinical trial targeting ankylosing spondyli...
2022-01-19 08:00
4374
CliniSys acquires HORIZON Lab Systems and combines with Sunquest Information Systems to create one of the world's largest organizations dedicated to diagnostics and laboratory informatics
· Combined group to enable better public health outcomes through innovation in diagnostics and laboratory informatics technology TUCSON, Arizona, Jan. 18, 2022 /PRNewswire/ -- CliniSys is announcing the recent acquisition of HORIZON Lab Systems and the combination with Sunquest Information Syst...
2022-01-18 22:00
2562
I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors
SHANGHAI and GAITHERSBURG, Md., Jan. 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in itsChina phase ...
2022-01-18 21:00
2294
CN Energy Signs Operation & Management Agreement; Enters Multi-Billion Dollar Pharmaceutical Excipients Market
LISHUI, China, Jan. 18, 2022 /PRNewswire/ -- CN Energy Group. Inc. (the "Company") today announced that its subsidiary Hangzhou Forasen Technology Co., Ltd. signed an operation and management ("O&M") agreement (the "Agreement") with HuaiNan JiaHe New Materials Co., Ltd. ("JiaHe") and JiaHe's acti...
2022-01-18 21:00
2489
LigoLab Applauded by Frost & Sullivan for Transforming Diagnostic Laboratories with its All-in-One Integrated LIS & RCM Platform
SAN ANTONIO, Jan. 18, 2022 /PRNewswire/ -- Frost & Sullivan recently analyzed the North American Laboratory Information Systems Industry and recognizesLigoLab as the 2022 Competitive Strategy Leadership Award winner for improving the efficiency of diagnostic laboratories and transforming them int...
2022-01-18 21:00
2376
Akeso's AK117 (CD47 monoclonal antibody) in Combination with AK112 (PD-1/VEGF bi-specific antibody) to Initiate a Phase Ib/II Clinical Trial with or without Chemotherapy for the Treatment of Advanced Malignant Tumors
HONG KONG, Jan. 18, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announces that Ligufalimab (CD47 monoclonal antibody, research and development code: AK117), the novel immuno-oncology drug independently developed by the Company, combined with Ivonescimab (PD-1/VEGF bi-specific antibody, research an...
2022-01-18 20:44
2814
Servier Group Reports Financial Year 2020/2021 Annual Results, R&D Strategy and Pipeline
- Consolidated revenue of €4.725 billion, up +4.3% at constant rates (+0.8% at current rates) - Revenue for brand-name medicines of €3.306 billion +4.8% at constant rates (+0.6% at current rates) and €1.419 billion for the generics +2.9% at constant rates (+1.1% at current rates) - An accelerat...
2022-01-18 20:00
2714
Ascletis Announces Signing of Ritonavir Tablet Purchase Agreement with Phokam Pharmaceutical Import-Export Co., Ltd of Laos
HANGZHOU and SHAOXING, China, Jan. 18, 2022 /PRNewswire/ -- Ascletis Pharma Inc. ("Ascletis") (HKEX: 1672) today announces signing of the ritonavir tablet purchase agreement between Phokam Pharmaceutical Import-Export Co., Ltd (as buyer) ofLaos and Ascletis Pharmaceuticals Co., Ltd. (as seller), ...
2022-01-18 18:00
3841
MindRank Begins IND-enabling Studies of its first AI-designed Drug, 8 Months After Program Initiation
HANGZHOU, China, Jan. 18, 2022 /PRNewswire/ -- MindRank AI, an artificial intelligence (AI) driven biotech company, today announced that the company has nominated a preclinical candidate (PCC) for an important class B GPCR drug target, 8 Months After Program Initiation. Historically, the developm...
2022-01-18 17:17
2274
Dermaliq Therapeutics Signs USD 15 Million Series A Round to Advance Three Transformative Drug Therapies into Clinical Trials
WILMINGTON, Del., Jan. 18, 2022 /PRNewswire/ -- Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd. today announced the establishment of Dermaliq Therapeutics, Inc (Dermaliq), a newly formedDelaware -based pharmaceutical development company, and the signing of aUSD 1...
2022-01-18 17:00
3004
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 273 media titles]
2026-10-09 13:21The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
[Picked up by 263 media titles]
2026-10-05 13:24